{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-009155","form_type":"8-K","ticker":"CURX","cik":"0002025942","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.026267+00:00","generated_at":"2026-05-15T19:03:33.146560+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Curanex Pharmaceuticals formalizes CEO/COO agreements; base salaries $393,600 and $180,000","bullets":["CEO Jun Liu: annual base salary $393,600, three-year term, plus $3,998/month auto lease.","COO Dr. Liqin Xie: annual salary $180,000, at-will employment, three-month severance on without-cause termination.","CEO served without compensation from Feb 2024 to Aug 2025; received $325,000.08 for past services through March 1, 2026.","Both agreements include 18-month non-compete (CEO), non-solicitation, and clawback provisions under policy effective Aug 12, 2025.","Termination without cause or for good reason triggers 3 months' salary continuation and immediate equity vesting for both."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-009155","json":"https://secwatch.observer/filing/0001493152-26-009155.json","markdown":"https://secwatch.observer/filing/0001493152-26-009155.md","text":"https://secwatch.observer/filing/0001493152-26-009155.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/0001493152-26-009155-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2025942/000149315226009155/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T19:03:33.146560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}